3,186 results match your criteria Nature Reviews Drug Discovery[Journal]


Applications of machine learning in drug discovery and development.

Nat Rev Drug Discov 2019 Apr 11. Epub 2019 Apr 11.

Pfizer Worldwide Research and Development, Cambridge, MA, USA.

Drug discovery and development pipelines are long, complex and depend on numerous factors. Machine learning (ML) approaches provide a set of tools that can improve discovery and decision making for well-specified questions with abundant, high-quality data. Opportunities to apply ML occur in all stages of drug discovery. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41573-019-0024-5
Publisher Site
http://dx.doi.org/10.1038/s41573-019-0024-5DOI Listing
April 2019
4 Reads

Therapeutic targeting of trained immunity.

Nat Rev Drug Discov 2019 Apr 9. Epub 2019 Apr 9.

Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands.

Immunotherapy is revolutionizing the treatment of diseases in which dysregulated immune responses have an important role. However, most of the immunotherapy strategies currently being developed engage the adaptive immune system. In the past decade, both myeloid (monocytes, macrophages and dendritic cells) and lymphoid (natural killer cells and innate lymphoid cells) cell populations of the innate immune system have been shown to display long-term changes in their functional programme through metabolic and epigenetic programming. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41573-019-0025-4DOI Listing

A call for a global 'bigger' data approach to Alzheimer disease.

Nat Rev Drug Discov 2018 Jul 6. Epub 2018 Jul 6.

Neuroscience Therapeutic Area, Takeda Research & Development, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd.2018.86DOI Listing
July 2018
4 Reads

Sleep protects against atherosclerosis.

Authors:
Sarah Crunkhorn

Nat Rev Drug Discov 2019 Mar 12. Epub 2019 Mar 12.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00041-8DOI Listing
March 2019
1 Read

Reprogrammed α-cells reverse diabetes.

Authors:
Sarah Crunkhorn

Nat Rev Drug Discov 2019 Mar 12. Epub 2019 Mar 12.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00039-2DOI Listing
March 2019
2 Reads

Upcoming market catalysts in Q2 2019.

Authors:
Travis Zuroske

Nat Rev Drug Discov 2019 Mar 12. Epub 2019 Mar 12.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00048-1DOI Listing
March 2019
2 Reads

Targeting polyamines in neuroblastoma.

Authors:
Sarah Crunkhorn

Nat Rev Drug Discov 2019 Mar 12. Epub 2019 Mar 12.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00042-7DOI Listing
March 2019
2 Reads

Molecular chaperone treats encephalopathy.

Authors:
Sarah Crunkhorn

Nat Rev Drug Discov 2019 Mar 12. Epub 2019 Mar 12.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00040-9DOI Listing
March 2019
1 Read

Drug pricing under the spotlight.

Authors:
Asher Mullard

Nat Rev Drug Discov 2019 Mar 12. Epub 2019 Mar 12.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00044-5DOI Listing
March 2019
2 Reads

Roche, Biogen and AbbVie stake new gene therapy claims.

Authors:
Asher Mullard

Nat Rev Drug Discov 2019 Mar 12. Epub 2019 Mar 12.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00045-4DOI Listing

Top drugs and companies by sales in 2018.

Authors:
Lisa Urquhart

Nat Rev Drug Discov 2019 Mar 12. Epub 2019 Mar 12.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00049-0DOI Listing
March 2019
1 Read

Bahija Jallal.

Authors:

Nat Rev Drug Discov 2019 Mar 8. Epub 2019 Mar 8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00050-7DOI Listing
March 2019
2 Reads

First targeted protein degrader hits the clinic.

Authors:
Asher Mullard

Nat Rev Drug Discov 2019 Mar 6. Epub 2019 Mar 6.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00043-6DOI Listing

Supersized virtual screening offers potent leads.

Authors:
Asher Mullard

Nat Rev Drug Discov 2019 Mar 5. Epub 2019 Mar 5.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00037-4DOI Listing
March 2019
2 Reads

Turning up mitophagy in Alzheimer disease.

Authors:
Katie Kingwell

Nat Rev Drug Discov 2019 Mar 4. Epub 2019 Mar 4.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00035-6DOI Listing
March 2019
2 Reads

New route to sepsis therapy.

Authors:
Sarah Crunkhorn

Nat Rev Drug Discov 2019 Mar 4. Epub 2019 Mar 4.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00034-7DOI Listing
March 2019
2 Reads

Repurposing CCR5 inhibitors for stroke recovery.

Nat Rev Drug Discov 2019 Mar 4. Epub 2019 Mar 4.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00038-3DOI Listing
March 2019
2 Reads

Tortoise-inspired device for oral delivery of biologics.

Authors:
Megan Cully

Nat Rev Drug Discov 2019 Mar 1. Epub 2019 Mar 1.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00036-5DOI Listing
March 2019
3 Reads

Massive NIH-industry project opens portals to target validation.

Authors:
Elie Dolgin

Nat Rev Drug Discov 2019 Feb 27. Epub 2019 Feb 27.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00033-8DOI Listing
February 2019
2 Reads

Unlocking the power of translational medicine.

Nat Rev Drug Discov 2019 Feb 18. Epub 2019 Feb 18.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00030-xDOI Listing
February 2019
1 Read

Publisher Correction: The current state and future directions of RNAi-based therapeutics.

Nat Rev Drug Discov 2019 Mar 18. Epub 2019 Mar 18.

Department of Molecular and Cellular Biology, Beckman Research Institute, City of Hope, Duarte, CA, USA.

The use of the names for patisiran has been made consistent throughout the article in line with the journal style and typographical errors have been corrected. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41573-019-0023-6
Publisher Site
http://dx.doi.org/10.1038/s41573-019-0023-6DOI Listing
March 2019
6 Reads

AMP-activated protein kinase: the current landscape for drug development.

Nat Rev Drug Discov 2019 Mar 13. Epub 2019 Mar 13.

Cellular Stress Group, Medical Research Council London Institute of Medical Sciences, Hammersmith Hospital, Imperial College, London, UK.

Since the discovery of AMP-activated protein kinase (AMPK) as a central regulator of energy homeostasis, many exciting insights into its structure, regulation and physiological roles have been revealed. While exercise, caloric restriction, metformin and many natural products increase AMPK activity and exert a multitude of health benefits, developing direct activators of AMPK to elicit beneficial effects has been challenging. However, in recent years, direct AMPK activators have been identified and tested in preclinical models, and a small number have entered clinical trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41573-019-0019-2DOI Listing
March 2019
1 Read

Moving upstream in anticancer drug development.

Nat Rev Drug Discov 2019 Mar;18(3):159-160

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-018-00006-3DOI Listing

Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges.

Nat Rev Drug Discov 2019 Mar 11. Epub 2019 Mar 11.

INSERM UMR 1163, Laboratory of Human Lymphohematopoiesis, Paris, France.

Pioneering gene therapy trials have shown that the genetic engineering of haematopoietic stem and progenitor cells can be an alternative to allogeneic transplantation in the treatment of primary immunodeficiencies. Early trials also highlighted the risk of insertional mutagenesis and oncogene transactivation associated with the first generation of gammaretroviral vectors. These events prompted the development of safer, self-inactivating lentiviral or gammaretroviral vectors. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41573-019-0020-9
Publisher Site
http://dx.doi.org/10.1038/s41573-019-0020-9DOI Listing
March 2019
9 Reads

Prospects for pharmacological targeting of pseudokinases.

Nat Rev Drug Discov 2019 Mar 8. Epub 2019 Mar 8.

Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, USA.

Pseudokinases are members of the protein kinase superfamily but signal primarily through noncatalytic mechanisms. Many pseudokinases contribute to the pathologies of human diseases, yet they remain largely unexplored as drug targets owing to challenges associated with modulation of their biological functions. Our understanding of the structure and physiological roles of pseudokinases has improved substantially over the past decade, revealing intriguing similarities between pseudokinases and their catalytically active counterparts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41573-019-0018-3DOI Listing

The current state and future directions of RNAi-based therapeutics.

Nat Rev Drug Discov 2019 Mar 7. Epub 2019 Mar 7.

Department of Molecular and Cellular Biology, Beckman Research Institute, City of Hope, Duarte, CA, USA.

The RNA interference (RNAi) pathway regulates mRNA stability and translation in nearly all human cells. Small double-stranded RNA molecules can efficiently trigger RNAi silencing of specific genes, but their therapeutic use has faced numerous challenges involving safety and potency. However, August 2018 marked a new era for the field, with the US Food and Drug Administration approving patisiran, the first RNAi-based drug. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41573-019-0017-4
Publisher Site
http://dx.doi.org/10.1038/s41573-019-0017-4DOI Listing
March 2019
37 Reads

FDA plans Office of Drug Evaluation Science.

Authors:
Asher Mullard

Nat Rev Drug Discov 2019 Mar;18(3):164

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00029-4DOI Listing
March 2019
4 Reads

Neglected disease R&D funding hits new high.

Authors:
Asher Mullard

Nat Rev Drug Discov 2019 Mar;18(3):164

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00027-6DOI Listing

Pharmaceutical market growth set to slow?

Authors:
Asher Mullard

Nat Rev Drug Discov 2019 Mar;18(3):164

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00028-5DOI Listing
March 2019
3 Reads

Uncoupling resistance to cancer immunotherapy.

Authors:
Katie Kingwell

Nat Rev Drug Discov 2019 Mar;18(3):171

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00025-8DOI Listing
March 2019
1 Read

Hal Barron.

Authors:
Asher Mullard

Nat Rev Drug Discov 2019 Mar;18(3):166-167

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00026-7DOI Listing
March 2019
2 Reads

Converting cancer cells to fat.

Authors:
Sarah Crunkhorn

Nat Rev Drug Discov 2019 Mar;18(3):174

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00021-yDOI Listing
March 2019
1 Read

Targeted therapy for chordoma.

Authors:
Sarah Crunkhorn

Nat Rev Drug Discov 2019 Mar;18(3):174

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00022-xDOI Listing

Eliminating disseminated tumour cells.

Authors:
Sarah Crunkhorn

Nat Rev Drug Discov 2019 Mar;18(3):174

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00023-wDOI Listing
March 2019
1 Read

Patent-evading drug synthesis.

Authors:
Sarah Crunkhorn

Nat Rev Drug Discov 2019 Mar;18(3):174

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00024-9DOI Listing
March 2019
4 Reads

CRISPR restores expression in models of vision loss.

Authors:
Megan Cully

Nat Rev Drug Discov 2019 Mar;18(3):174

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00016-9DOI Listing

Designing cytokine mimics can optimize cancer therapy potential.

Authors:
Sarah Crunkhorn

Nat Rev Drug Discov 2019 Mar;18(3):173

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00020-zDOI Listing
March 2019
1 Read

A stem-cell-derived eye patch for macular degeneration.

Nat Rev Drug Discov 2019 Mar;18(3):172

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00017-8DOI Listing
March 2019
1 Read

Infectious disease vaccines.

Nat Rev Drug Discov 2019 Mar;18(3):169-170

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-018-00011-6DOI Listing
March 2019
1 Read

Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond.

Nat Rev Drug Discov 2019 Feb 13. Epub 2019 Feb 13.

DKTK Brain Cancer Metabolism Group, German Cancer Research Center (DKFZ), INF 280, Heidelberg, Germany.

L-Tryptophan (Trp) metabolism through the kynurenine pathway (KP) is involved in the regulation of immunity, neuronal function and intestinal homeostasis. Imbalances in Trp metabolism in disorders ranging from cancer to neurodegenerative disease have stimulated interest in therapeutically targeting the KP, particularly the main rate-limiting enzymes indoleamine-2,3-dioxygenase 1 (IDO1), IDO2 and tryptophan-2,3-dioxygenase (TDO) as well as kynurenine monooxygenase (KMO). However, although small-molecule IDO1 inhibitors showed promise in early-stage cancer immunotherapy clinical trials, a phase III trial was negative. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41573-019-0016-5DOI Listing
February 2019

Antibodies and venom peptides: new modalities for ion channels.

Nat Rev Drug Discov 2019 Feb 6. Epub 2019 Feb 6.

Department of Physiology & Membrane Biology, University of California Davis, Davis, CA, USA.

Ion channels play fundamental roles in both excitable and non-excitable tissues and therefore constitute attractive drug targets for myriad neurological, cardiovascular and metabolic diseases as well as for cancer and immunomodulation. However, achieving selectivity for specific ion channel subtypes with small-molecule drugs has been challenging, and there currently is a growing trend to target ion channels with biologics. One approach is to improve the pharmacokinetics of existing or novel venom-derived peptides. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41573-019-0013-8
Publisher Site
http://dx.doi.org/10.1038/s41573-019-0013-8DOI Listing
February 2019
23 Reads

2018 FDA drug approvals.

Authors:
Asher Mullard

Nat Rev Drug Discov 2019 Feb;18(2):85-89

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41573-019-00014-xDOI Listing
February 2019
11 Reads

2018 FDA approvals hit all time high - but average value slips again.

Nat Rev Drug Discov 2019 Feb;18(2):90

Boston Consulting Group, Boston, Zürich, Switzerland.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/d41573-019-00004-z
Publisher Site
http://dx.doi.org/10.1038/d41573-019-00004-zDOI Listing
February 2019
14 Reads

Biopharma dealmaking in 2018.

Nat Rev Drug Discov 2019 Feb;18(2):93-94

View Article

Download full-text PDF

Source
http://www.nature.com/articles/d41573-019-00013-y
Publisher Site
http://dx.doi.org/10.1038/d41573-019-00013-yDOI Listing
February 2019
12 Reads

Developing closed-loop neuromodulatory devices.

Authors:
Sarah Crunkhorn

Nat Rev Drug Discov 2019 Feb;18(2):98

Nature Reviews Drug Discovery, .

View Article

Download full-text PDF

Source
http://www.nature.com/articles/d41573-019-00011-0
Publisher Site
http://dx.doi.org/10.1038/d41573-019-00011-0DOI Listing
February 2019
9 Reads

Role of the Protein Data Bank.

Authors:
Sarah Crunkhorn

Nat Rev Drug Discov 2019 Feb;18(2):98

Nature Reviews Drug Discovery, .

View Article

Download full-text PDF

Source
http://www.nature.com/articles/d41573-019-00010-1
Publisher Site
http://dx.doi.org/10.1038/d41573-019-00010-1DOI Listing
February 2019
10 Reads